Literature DB >> 2582778

Pharmacokinetics of recombinant human erythropoietin after SC administration and in long-term IV treatment in patients on maintenance hemodialysis.

H H Neumayer1, J Brockmöller, E Fritschka, I Roots, P Scigalla, M Wattenberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2582778     DOI： 10.1159/000417889

Source DB:  PubMed          Journal:  Contrib Nephrol        ISSN： 0302-5144            Impact factor:   1.580


× No keyword cloud information.
  11 in total

1.  Population pharmacokinetic and pharmacodynamic model-based comparability assessment of a recombinant human Epoetin Alfa and the Biosimilar HX575.

Authors:  Xiaoyu Yan; Philip J Lowe; Martin Fink; Alexander Berghout; Sigrid Balser; Wojciech Krzyzanski
Journal:  J Clin Pharmacol       Date:  2011-12-12       Impact factor: 3.126

Review 2.  Clinical pharmacokinetics and pharmacodynamics of erythropoiesis-stimulating agents.

Authors:  Sameer Doshi; Wojciech Krzyzanski; Susan Yue; Steven Elliott; Andrew Chow; Juan José Pérez-Ruixo
Journal:  Clin Pharmacokinet       Date:  2013-12       Impact factor: 6.447

3.  The pharmacokinetics of recombinant human erythropoietin after subcutaneous injection at different sites.

Authors:  J D Jensen; L W Jensen; J K Madsen
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

Review 4.  Clinical pharmacokinetics of epoetin (recombinant human erythropoietin).

Authors:  I C Macdougall; D E Roberts; G A Coles; J D Williams
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

Review 5.  Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure.

Authors:  C J Dunn; A Markham
Journal:  Drugs       Date:  1996-02       Impact factor: 9.546

6.  Pharmacokinetics of epoetin in haemodialysis patients after subcutaneous administration: influence of chronic treatment.

Authors:  J P Schouten; G Voorhorst; A R Helbing; J W Janssen; P P Diderich; C T Op de Hoek
Journal:  Pharm World Sci       Date:  1993-12-17

7.  Pharmacokinetics of epoetin (recombinant human erythropoietin) after long term therapy in patients undergoing haemodialysis and haemofiltration.

Authors:  U Gladziwa; U Klotz; K Bäumer; R Zollinger; H Mann; H G Sieberth
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

8.  Pharmacokinetics of recombinant human erythropoietin applied subcutaneously to children with chronic renal failure.

Authors:  A Braun; R Ding; C Seidel; T Fies; A Kurtz; K Schärer
Journal:  Pediatr Nephrol       Date:  1993-02       Impact factor: 3.714

Review 9.  Epoetin Beta: a review of its clinical use in the treatment of anaemia in patients with cancer.

Authors:  Susan M Cheer; Antona J Wagstaff
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients.

Authors:  J Brockmöller; J Köchling; W Weber; M Looby; I Roots; H H Neumayer
Journal:  Br J Clin Pharmacol       Date:  1992-12       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.